FP9 CS

FP9 CS is a recombinant viral vector vaccine candidate developed for malaria. It uses the FP9 strain of fowlpox virus as a delivery platform to express the circumsporozoite (CS) protein antigen from Plasmodium falciparum, the parasite responsible for most cases of severe malaria. The vaccine is designed to induce an immune response against the circumsporozoite protein, aiming to prevent infection by targeting the parasite at its pre-erythrocytic stage. Clinical studies have evaluated its safety and immunogenicity in healthy adult volunteers, often as part of a prime-boost regimen with other vaccines such as MVA CS[1][5].

Other names

FP9 CircumsporozoiteFP-9 CircumsporozoiteFP 9 CircumsporozoiteFP9-CSFP-9-CSFP 9-CS